These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29708436)

  • 1. PROLACTIN LEVELS DO NOT RISE AMONG TRANSGENDER WOMEN TREATED WITH ESTRADIOL AND SPIRONOLACTONE.
    Bisson JR; Chan KJ; Safer JD
    Endocr Pract; 2018 Jul; 24(7):646-651. PubMed ID: 29708436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TESTOSTERONE LEVELS ACHIEVED BY MEDICALLY TREATED TRANSGENDER WOMEN IN A UNITED STATES ENDOCRINOLOGY CLINIC COHORT.
    Liang JJ; Jolly D; Chan KJ; Safer JD
    Endocr Pract; 2018 Feb; 24(2):135-142. PubMed ID: 29144822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial.
    Burinkul S; Panyakhamlerd K; Suwan A; Tuntiviriyapun P; Wainipitapong S
    J Sex Med; 2021 Jul; 18(7):1299-1307. PubMed ID: 34274044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low estrogen doses normalize testosterone and estradiol levels to the female range in transgender women.
    Cunha FS; Domenice S; Sircili MHP; Mendonca BB; Costa EMF
    Clinics (Sao Paulo); 2018; 73():e86. PubMed ID: 29723345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Endocrine and Metabolic Effects of Testosterone Suppressive Agents in Transgender Women.
    Sofer Y; Yaish I; Yaron M; Bach MY; Stern N; Greenman Y
    Endocr Pract; 2020 Aug; 26(8):883-890. PubMed ID: 33471679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ESTROGEN LEVELS DO NOT RISE WITH TESTOSTERONE TREATMENT FOR TRANSGENDER MEN.
    Chan KJ; Jolly D; Liang JJ; Weinand JD; Safer JD
    Endocr Pract; 2018 Apr; 24(4):329-333. PubMed ID: 29561193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women.
    Fung R; Hellstern-Layefsky M; Tastenhoye C; Lega I; Steele L
    J Sex Med; 2016 Nov; 13(11):1765-1772. PubMed ID: 27693265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concerning the Article by Fung et al, Titled "Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women".
    Defreyne J; T'Sjoen G
    J Sex Med; 2017 Jan; 14(1):172-173. PubMed ID: 28065354
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to "Letter to the Editor Concerning the Paper by Fung et al titled 'Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women".
    Fung R; Lega I
    J Sex Med; 2017 Jan; 14(1):173-174. PubMed ID: 28065355
    [No Abstract]   [Full Text] [Related]  

  • 10. Reproductive Endocrinology Reference Intervals for Transgender Women on Stable Hormone Therapy.
    Greene DN; Schmidt RL; Winston McPherson G; Rongitsch J; Imborek KL; Dickerson JA; Drees JC; Humble RM; Nisly N; Dole NJ; Dane SK; Frerichs J; Krasowski MD
    J Appl Lab Med; 2021 Jan; 6(1):15-26. PubMed ID: 32674116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of antiandrogens on prolactin levels among transgender women on estrogen therapy: A systematic review.
    Wilson LM; Baker KE; Sharma R; Dukhanin V; McArthur K; Robinson KA
    Int J Transgend Health; 2020; 21(4):391-402. PubMed ID: 34993517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-Dose Cyproterone Acetate Treatment for Transgender Women.
    Even Zohar N; Sofer Y; Yaish I; Serebro M; Tordjman K; Greenman Y
    J Sex Med; 2021 Jul; 18(7):1292-1298. PubMed ID: 34176757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of antiandrogens and feminization in transgender women.
    Angus LM; Nolan BJ; Zajac JD; Cheung AS
    Clin Endocrinol (Oxf); 2021 May; 94(5):743-752. PubMed ID: 32926454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. INCREASED RATES OF SMOKING CESSATION OBSERVED AMONG TRANSGENDER WOMEN RECEIVING HORMONE TREATMENT.
    Myers SC; Safer JD
    Endocr Pract; 2017 Jan; 23(1):32-36. PubMed ID: 27682351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy.
    Angus L; Leemaqz S; Ooi O; Cundill P; Silberstein N; Locke P; Zajac JD; Cheung AS
    Endocr Connect; 2019 Jul; 8(7):935-940. PubMed ID: 31234145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Hormone Concentrations in Transgender Youth Receiving Estradiol.
    Sumerwell C; Carlin K; Walsh E; Hodax JK
    Endocr Pract; 2024 Feb; 30(2):155-159. PubMed ID: 38029927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of Venous Thromboembolism in Transgender Women Receiving Oral Estradiol.
    Arnold JD; Sarkodie EP; Coleman ME; Goldstein DA
    J Sex Med; 2016 Nov; 13(11):1773-1777. PubMed ID: 27671969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperprolactinemia and association with prolactinoma in transwomen receiving gender affirming hormone treatment.
    Raven LM; Guttman-Jones M; Muir CA
    Endocrine; 2021 May; 72(2):524-528. PubMed ID: 33398769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of spironolactone and cyproterone acetate on breast growth in transgender people: a randomized clinical trial.
    Angus LM; Leemaqz SY; Kasielska-Trojan AK; Mikołajczyk M; Doery JCG; Zajac JD; Cheung AS
    J Clin Endocrinol Metab; 2024 Sep; ():. PubMed ID: 39288020
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.